|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.32 SEK | +0.44% |
|
-6.76% | +4.27% |
| Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
| Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Hansa Biopharma AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 134.09 million compared to SEK 154.53 million a year ago. Net loss was SEK 831.72 million compared to SEK 611.13 million a year ago.
Basic loss per share from continuing operations was SEK 15.83 compared to SEK 13.6 a year ago. Diluted loss per share from continuing operations was SEK 15.83 compared to SEK 13.6 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +4.27% | 137M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
HANSA BIOPHARMA AB 
